Innovating Works

HERMAN MUCKE PHARMA CONSULTANCY EU

Desconocido
SAVEBRAIN: Proof of principle for a first in class neuroprotective therapy in stroke and other acute neurodegen... MUCKE HERMANN participó en un H2020: ERC-2016-PoC Stroke represents currently one of the largest – if not the largest - unmet medical need: It is the second leading cause of death and the le...
2017-12-11 - 2019-09-30 | Financiado
REPO-TRIAL: An in silico based approach to improve the efficacy and precision of drug REPurpOsing TRIALs for a m... MUCKE HERMANN participó en un H2020: H2020-SC1-2016-2017 Our programme will develop an innovative in-silico based approach to improve the efficacy and precision of drug repurposing trials. We have...
2017-10-31 - 2024-01-31 | Financiado
* Datos extraídos de la documentos o webs disponibles en diferentes organismos públicos.